N-乙基-4-喹啉胺 | 5895-77-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: N-乙基-4-喹啉胺
• 英文名称: ethyl-quinolin-4-yl-amine
• 英文别名: N-Ethylquinolin-4-amine
• CAS: 5895-77-2
• 化学式: C₁₁H₁₂N₂
• 分子量: 172.23
• InChiKey: TTXHGYGDDOYSDB-UHFFFAOYSA-N

物化性质

• 沸点：
  319.2±17.0 °C(Predicted)
• 密度：
  1.127±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-氯-3-喹啉磺酸 在 硫酸 作用下， 以 水 为溶剂， 反应 7.0h， 生成 N-乙基-4-喹啉胺
  参考文献：
  名称：

  Synthesis of 4-Amino-3-quinolinesulfonic Acids and 4-Aminoquinolines

  摘要：

  The hydrolysis of 4-chloro-3-quinolinesulfonyl chloride (1) gives 4-chloro-3-quinolinesulfonic acid (2) or 1,4-dihydro-4-oxo-3-quinolinesulfonic acid (3). Compound (2) reacts with primary and secondary aliphatic or primary aromatic amines to give 4-amino-3-quinolinesulfonic acids (4). Desulfonation of quinolinesulfonic acids (2,3,4) yields 4(1H)-quinolinone or 4-aminoquinolines (5).

  DOI：

  10.3987/com-97-8003

文献信息

• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100168138A1

  公开（公告）日：2010-07-01

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• [EN] CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES<br/>[FR] ARYLALKYLAMINES MODULANT UN RECEPTEUR CALCIQUE
  申请人：AMGEN INC

  公开号：WO2003099776A1

  公开（公告）日：2003-12-04

  The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  该发明的化合物由以下一般结构（I）或其药用可接受盐所代表，以及含有它们的组合物，其中变量在此处定义，并且它们的用途是减少或抑制PTH分泌，包括减少或抑制PTH分泌的方法以及用于治疗或预防与骨骼疾病相关的疾病的方法，例如骨质疏松症，或与PTH过度分泌相关的疾病，例如甲状旁腺功能亢进症。该主题发明还涉及制备此类化合物的过程，以及在此类过程中有用的中间体。
• MATRIX FOR MALDI MASS SPECTROMETRY AND MALDIMASS SPECTROMETRY METHOD
  申请人：Shindo Mitsuru

  公开号：US20140151548A1

  公开（公告）日：2014-06-05

  Provided is a matrix for MALDI mass spectrometry that has a high ability of ionizing low-molecular-weight compounds, and makes it possible to make measurement in a negative ion mode. The matrix is a matrix for mass spectrometry that contains one or more compounds selected from the group consisting of compounds each represented by the following general formula (I), (II) or (III), and their salts thereof. In the formulae (I), (II) and (III), X and Z are each C or N; R 1 and R 5 are each selected from the group consisting of H, an alkyl group, a (substituted) aryl group, a (substituted) arylalkyl group, and a (substituted) heteroaryl group; R 2 and R 6 are each selected from the group consisting of H, an alkyl group, an alkoxyl group, an amino group, a halogen atom, a nitro group, an allyl group, a (substituted) aryl group, and a (substituted) heteroaryl group; and R 7 and R 8 are each selected from the group consisting of H and an amino group provided that a case where R 1 =R 2 =H, and a case where R 7 =R 8 =an amino group are excluded.

  提供的是一种用于MALDI质谱的矩阵，具有高能力电离低分子量化合物的能力，并使得在负离子模式下进行测量成为可能。该矩阵是一种质谱矩阵，包含从由以下通式（I）、（II）或（III）表示的化合物组成的化合物中选择的一个或多个化合物及其盐。在式（I）、（II）和（III）中，X和Z分别为C或N；R1和R5分别选择自H、烷基、（取代）芳基、（取代）芳基烷基和（取代）杂芳基组成的群；R2和R6分别选择自H、烷基、烷氧基、氨基、卤素原子、硝基、烯丙基、（取代）芳基和（取代）杂芳基组成的群；R7和R8分别选择自H和氨基，但排除R1=R2=H和R7=R8=氨基的情况。
• Hydrolysis of 4-Amino-3-qunolinesulfonamides
  作者：Leszek Skrzypek

  DOI：10.3987/com-98-8164

  日期：——

  Acid hydrolysis of 4-amino-3-quinolinesulfonamides (3) gives 1,4-dihydro-4-oxo-3-quinolinesulfonamides (4), 4-aminoquinolines (5) or a mixture of these compounds.
• CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES
  申请人：Amgen Inc.

  公开号：EP1509497A1

  公开（公告）日：2005-03-02